AVROBIO, Inc. (AVRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVRO Stock Price Chart Interactive Chart >
AVRO Price/Volume Stats
| Current price | $0.67 | 52-week high | $6.62 |
| Prev. close | $0.66 | 52-week low | $0.63 |
| Day low | $0.65 | Volume | 580,800 |
| Day high | $0.72 | Avg. volume | 528,434 |
| 50-day MA | $0.89 | Dividend yield | N/A |
| 200-day MA | $1.32 | Market Cap | 29.49M |
AVROBIO, Inc. (AVRO) Company Bio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest AVRO News From Around the Web
Below are the latest news stories about AVROBIO INC that investors may wish to consider to help them evaluate AVRO as an investment opportunity.
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual CongressCAMBRIDGE, Mass., September 27, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland. |
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for CystinosisCAMBRIDGE, Mass., September 20, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to AVR-RD-04, an investigational gene therapy for the treatment of cystinosis, a life-threatening disease that causes progressive multi-organ damage, including early, acute kidney disease progressing to end-stage ki |
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy TrialCAMBRIDGE, Mass., September 14, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC) and Health Research Authority (HRA) have approved the clinical trial application (CTA) submitted by AVROBIO’s collaborators at the University of Manchester, U.K. (UoM) for initiation of the Phase 1/2 clini |
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., September 08, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 58,000 restricted stock units (RSUs) to three new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). |
AVROBIO to Participate in Four Upcoming Investor Conferences in SeptemberCAMBRIDGE, Mass., August 31, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences: |
AVRO Price Returns
| 1-mo | -22.93% |
| 3-mo | -36.19% |
| 6-mo | -45.08% |
| 1-year | -88.06% |
| 3-year | -95.13% |
| 5-year | N/A |
| YTD | -82.60% |
| 2021 | -72.38% |
| 2020 | -30.75% |
| 2019 | 20.90% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...